Searching for indirect evidence and extending the network of studies for network meta-analysis: Case study in venous thromboembolic events prevention following elective total knee replacement surgery

Value in Health

Volumn 17, Issue 4, 2014, Pages 416-423

  Dequen, Pascale ^a   Sutton, Alex J ^a   Scott, David A ^b   Abrams, Keith R ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ICON PLC   (United Kingdom)

Author keywords

evidence synthesis; indirect treatment comparison; network meta analysis; relative effectiveness; venous thromboembolism

Indexed keywords

APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; PLACEBO; RIVAROXABAN;

ARTICLE; COCHRANE LIBRARY; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DECISION TREE; ELECTIVE SURGERY; EMBASE; HUMAN; KNEE ARTHROPLASTY; MEDLINE; META ANALYSIS; MONTE CARLO METHOD; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROBABILITY; PUBLICATION; SIMULATION; SYSTEMATIC REVIEW; TOTAL KNEE REPLACEMENT; UNITED KINGDOM; VENOUS THROMBOEMBOLISM;

EVIDENCE SYNTHESIS; INDIRECT TREATMENT COMPARISON; NETWORK META-ANALYSIS; RELATIVE EFFECTIVENESS; VENOUS THROMBOEMBOLISM;

ADULT; ARTHROPLASTY, REPLACEMENT, KNEE; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; HUMANS; MODELS, ECONOMIC; POSTOPERATIVE COMPLICATIONS; PYRAZOLES; PYRIDONES; VENOUS THROMBOEMBOLISM;

EID: 84903305578     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.02.013     Document Type: Article

References (30)

1. S. Kleijnen, E. George, and S. Goulden et al. Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 Jurisdictions Value Health 15 2012 954 960
2. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. 2011. Available from: www.cochrane-handbook.org. [Accessed October 15, 2012].
3. Centre for Reviews and Dissemination. Systematic Reviews CRD's Guidance for Undertaking Reviews in Health Care. York: Centre for Reviews and Dissemination, University of York. Available from: www.york.ac.uk. [Accessed August 28, 2012].
4. T. Lumley Network meta-analysis for indirect treatment comparisons Stat Med 21 2002 2313 2324
5. G. Lu, and A.E. Ades Combination of direct and indirect evidence in mixed treatment comparisons Stat Med 23 2004 3105 3124
6. N.J. Cooper, J. Peters, and M.C.W. Lai et al. How valuable are multiple treatment comparison methods in evidence-based health-care evaluation? Value Health 14 2011 371 380
7. N. Hawkins, D.A. Scott, and B. Woods How far do you go? Efficient searching for indirect evidence Med Decis Mak 29 2009 273 281
8. D.C. Hoaglin, N. Hawkins, and J.P. Jansen et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2 Value Health 14 2011 429 437
9. N. Hawkins, D.A. Scott, B.S. Woods, and N. Thatcher No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data Value Health 12 2009 996 1003
10. National Institute for Health and Care Excellence. Venous Thromboembolism - Reducing the Risk. Care guidelines CG92. London, UK: National Institute for Health and Care Excellence, 2010. Available from: guidance.nice.org.uk/CG92. [Accessed September 1, 2012].
11. National Institute for Health and Care Excellence. 2012. Apixaban for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Adults. Technology Appraisal TA245. London, UK: National Institute for Health and Care Excellence. Available from: www.nice.org.uk. [Accessed September 1, 2012].
12. National Institute for Health and Care Excellence. Dabigatran Etexilate for the Prevention of Venous Thromboembolism After Hip or Knee Replacement Surgery in Adults. Technology Appraisal TA157. London, UK: National Institute for Health and Care Excellence, 2008. Available from: www.nice.org.uk. [Accessed September 1, 2012].
13. National Institute for Health and Care Excellence. Rivaroxaban for the Prevention of Venous Thromboembolism After Total Hip or Total Knee Replacement in Adults. Technology Appraisal TA170. London, UK: National Institute for Health and Care Excellence, 2009. Available from: www.nice.org.uk. [Accessed September 1, 2012].
14. Bristol-Myers Squibb Pharmaceuticals Ltd. and Pfizer Ltd. Apixaban (Eliquis®) for the Prevention of Venous Thromboembolic Events in Adult Patients Who Have Undergone Elective Hip or Knee Replacement Surgery Venous Thromboembolism - Apixaban (Hip and Knee Surgery): Manufacturer Submission 2011 National Institute for Health and Care Excellence London, UK
15. Kleijnen Systematic Reviews Ltd. Apixaban for the Prevention of Venous Thromboembolism in People Undergoing Elective Knee and Hip Replacement Surgery Venous Thromboembolism - Apixaban (Hip and Knee Surgery): Evidence Review Group Report 2011 National Institute for Health and Care Excellence London, UK
16. M.R. Lassen, G.E. Raskob, and A. Gallus et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 2012 807 815
17. B.I. Eriksson, O.E. Dahl, and N. Rosencher et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thrombosis Haemostasis 5 2007 2178 2185
18. M.R. Lassen, W. Ageno, and L.C. Borris et al. (RECORD3 Investigators). Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786
19. D.J. Lunn, A. Thomas, N. Best, and D. Spiegelhalter WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility Stat Comput 10 2000 325 337
20. Ades AE, Welton N, Lu G. Introduction to Mixed Treatment Comparisons., Bristol, UK: University of Bristol. Available from: www.bristol.ac.uk. [Accessed October 23, 2012].
21. D.J. Spiegelhalter, N.G. Best, and B.P. Carlin et al. Bayesian measures of model complexity and fit J Royal Stat Soc Ser B (Stat Methodol) 64 2002 583 616
22. D.J. Spiegelhalter, K.R. Abrams, and J.P. Myles Bayesian Approaches to Clinical Trials and Health-Care Evaluation 2003 John Wiley & Sons Ltd. Chichester, UK
23. D.M. Caldwell, N.J. Welton, and A.E. Ades Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency J Clin Epidemiol 63 2010 875 882
24. E.C. Marshall, and D.J. Spiegelhalter Approximate cross-validatory predictive checks in disease mapping models Stat Med 22 2003 1649 1660
25. N.J. Welton, A.J. Sutton, and N.J. Copper Evidence Synthesis for Decision Making in Healthcare 2012 John Wiley & Sons Ltd Chichester, UK
26. C.J. Wang, J.W. Wang, and L.H. Weng et al. Prevention of deep-vein thrombosis after total knee arthroplasty in Asian patients: comparison of low-molecular-weight heparin and indomethacin J Bone Joint Surg 86-A 2004 136 140
27. A.E. Ades, I. Mavranezouli, and S. Dias et al. Network meta-analysis with competing risk outcomes Value Health 13 2004 976 983
28. N.J. Welton, N.J. Cooper, and A.E. Ades et al. Mixed treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals for treatment of influenza A and B Stat Med 27 2008 5620 5639
29. G. Lu, A.E. Ades, and A.J. Sutton et al. Meta-analysis of mixed treatment comparisons at multiple follow-up times Stat Med 26 2007 3681 3699
30. J. König, U. Krahn, and H. Binder Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons Stat Med 32 2013 5414 5429